Sara A. Almansour
Sharjah, SH, United Arab Emirates
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 16, 2026
HSR26-204: Baseline EORTC QLQ-C30 "Clinically Important" Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Prognostic value of patient-reported outcome thresholds on survival and adverse events in CLL/SLL: A pooled analysis of ibrutinib trials.
Journal: Therapeutic advances in hematology
Published: November 24, 2025
Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma.
Journal: European journal of haematology
Published: January 17, 2025
Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
Journal: Therapeutic advances in medical oncology
Published: March 25, 2024
Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials.
Journal: Scientific reports
Published: August 22, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026